Glenmark Pharmaceuticals announced the launch of Potassium Phosphates Injection USP in multiple dosage strengths, including 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL single-dose vials, as well as 150 mmol P / 220 mEq K per 50 mL pharmacy bulk package vials.The company said its Potassium Phosphates Injection is bioequivalent and therapeutically equivalent to the reference listed drug from Fresenius Kabi.
Glenmark plans to begin distribution of the product in March 2026.
According to IQVIA sales data for the 12-month period ending January 2026, the Potassium Phosphates Injection market recorded annual sales of approximately $50.7 million.Marc Kikuchi, President and Business Head for North America at Glenmark, said the launch will help expand the company’s portfolio in the institutional channel and reinforce its commitment to providing quality and affordable injectable medicines to patients.
Shares of Glenmark Pharmaceuticals were trading 0.39% higher at ₹2,179.10 on Friday. The stock has gained nearly 8% so far in 2026.
